Cross-reactivity of epoetin alfa and darbepoetin alfa with two immunochemiluminometric erythropoietin assays

Clinica Chimica Acta

Volumn 383, Issue 1-2, 2007, Pages 184-185

  Mongia, Shella K ^a   Owen, William E ^b   Roberts, William L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

CHEMOLUMINESCENCE; CROSS REACTION; DEVICE; DRUG DETERMINATION; IMMUNOASSAY; INTERMETHOD COMPARISON; LETTER; PRIORITY JOURNAL;

CHEMILUMINESCENT MEASUREMENTS; CROSS REACTIONS; DRUG MONITORING; EPOETIN ALFA; ERYTHROPOIETIN; HUMANS; IMMUNOASSAY;

EID: 34347344896     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.04.026     Document Type: Letter

References (6)

1. Marsden J.T. Erythropoietin-measurement and clinical applications. Ann Clin Biochem 43 (2006) 97-104
2. Owen W.E., and Roberts W.L. Performance characteristics of the IMMULITE 2000 erythropoietin assay. Clin Chim Acta 340 (2004) 213-217
3. Elliott S., Egrie J., Browne J., Lorenzini R., Busse L., Rogers N., et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 32 (2004) 1146-1155
4. Wide L., Wikstrom B., and Eriksson K. A new principle suggested for detection of darbepoetin-α (NESP) doping. Ups J Med Sci 108 (2003) 229-238
5. Combe C., Tredree R.L., and Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 25 (2005) 954-962
6. Deechongkit S., Aoki K.H., Park S.S., and Kerwin B.A. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci 95 (2006) 1931-1943